Search research articles
Contact Us
Filters
Showing results (1-10 of 261) with videos related to
Page
of 27
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 4, 2019
Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes
Tomas Kalincik
Neuroepidemiology
|
May 23, 2015
Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review
Tomas Kalincik
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 9, 2018
Where there is inflammation, treatment may reduce disability progression - Yes
Tomas Kalincik
Neurology
|
March 17, 2019
Effectiveness of oral multiple sclerosis therapies in clinical context
Tomas Kalincik
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 15, 2024
The era of harmonised disability outcomes in multiple sclerosis
Tomas Kalincik
Brain : a Journal of Neurology
|
March 8, 2018
Reply: Towards personalized therapy for multiple sclerosis: limitations of observational data
Tomas Kalincik
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
May 3, 2017
Stop inflammation and you stop neurodegeneration in MS - NO
Tomas Kalincik
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 25, 2018
Comparisons of therapies in different scenarios help complete the puzzle
Tomas Kalincik
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 21, 2023
How effective is effective enough?
Tomas Kalincik, Amy Brodtmann
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 9, 2016
Observational data: Understanding the real MS world
Tomas Kalincik, Helmut Butzkueven
Page
of 27
Search research articles
Search
Showing results (1-10 of 261) with videos related to
Sort By:
Page
of 27
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 4, 2019
Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes
Tomas Kalincik
Neuroepidemiology
|
May 23, 2015
Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review
Tomas Kalincik
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 9, 2018
Where there is inflammation, treatment may reduce disability progression - Yes
Tomas Kalincik
Neurology
|
March 17, 2019
Effectiveness of oral multiple sclerosis therapies in clinical context
Tomas Kalincik
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 15, 2024
The era of harmonised disability outcomes in multiple sclerosis
Tomas Kalincik
Brain : a Journal of Neurology
|
March 8, 2018
Reply: Towards personalized therapy for multiple sclerosis: limitations of observational data
Tomas Kalincik
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
May 3, 2017
Stop inflammation and you stop neurodegeneration in MS - NO
Tomas Kalincik
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 25, 2018
Comparisons of therapies in different scenarios help complete the puzzle
Tomas Kalincik
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 21, 2023
How effective is effective enough?
Tomas Kalincik, Amy Brodtmann
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 9, 2016
Observational data: Understanding the real MS world
Tomas Kalincik, Helmut Butzkueven
Page
of 27